Clinical Trials Archives - Pharma Globenewswire

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

DelveInsight’s “Lassa Fever – Pipeline Insight, 2026” provides a detailed view of the evolving pipeline, emphasizing efforts to deliver first-in-class therapies and vaccines to endemic populations. The report highlights global R&D activity, platform technologies, and regulatory incentives accelerating development timelines.Lassa Fever, an

9 April 2026

Clinical Trials·Reports

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise in aging populations is significantly increasing the at-risk patient base.

9 April 2026

Clinical Trials·Reports·Uncategorised

Migraine Clinical Trial Analysis Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space

The migraine therapeutics market is experiencing strong momentum as rising global prevalence, better diagnostic recognition, and expanding patient awareness steadily grow the treated population. Adoption of targeted therapies such as CGRP inhibitors and gepants continues to accelerate, driven by their superior tolerability

9 April 2026

Clinical Trials

Myelodysplastic Syndrome Clinical Trial Pipeline Gains Momentum: 120+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insights 2026” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics

13 March 2026

Clinical Trials

ALK Inhibitor Clinical Trial Pipeline Gains Momentum: 15+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “ALK Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the ALK Inhibitors pipeline landscape. It covers the ALK Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK

13 March 2026

Imviva Biotech Receives FDA Orphan Drug Designation

Clinical Trials

FDA Grants Orphan Drug Designation to CTD402, an Off‑the‑Shelf Anti‑CD7 CAR‑T Therapy, for Rare T‑Cell Leukemias and Lymphomas

The Food and Drug Administration (FDA) has granted orphan drug designation to CTD402, an investigational allogeneic anti‑CD7 CAR‑T cell therapy from Imviva Biotech, for the treatment of patients with relapsed or refractory T‑cell acute lymphoblastic leukemia (T‑ALL) and lymphoblastic lymphoma (T‑LBL). This

6 February 2026

Clinical Trials

Shilpa Medicare’s Biologicals Unit Secures FDA Orphan Drug Designation for Investigational Monoclonal Antibody Targeting Rare Blood Cancers

Shilpa Biologicals Private Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, in collaboration with Switzerland-based mAbTree Biologics AG, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to their investigational biologic product. The designation covers a

5 February 2026

Clinical Trials

FDA Grants Breakthrough Therapy Designation to Bezuclastinib Plus Sutent for Advanced GIST After GLEEVEC Failure

The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to bezuclastinib in combination with Sutent (sunitinib) for adults with advanced gastrointestinal stromal tumors (GIST) whose disease has progressed on, or become resistant to, GLEEVEC (imatinib), according to a recent update

5 February 2026

Autism-Spectrum-Disorder-Pipeline-Insights

Clinical Trials·Market Insights

Autism Spectrum Disorder Pipeline Insight 2025: Emerging Therapies, Clinical Trial Updates, and Regulatory Progress

The Autism Spectrum Disorder (ASD) Pipeline Insight 2025 highlights a rapidly evolving therapeutic landscape, driven by increasing disease prevalence, advances in neurodevelopmental research, and growing investment in precision medicine. According to DelveInsight, more than 18 biopharmaceutical companies are actively developing 20+ investigational

4 February 2026

Clinical Trials

The FDA Grants Fast Track Designation to Novel GPRC5D/CD3 Bispecific Antibody LBL‑034 for Relapsed/Refractory Multiple Myeloma

The Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to LBL‑034, an investigational GPRC5D/CD3 bispecific T‑cell engager, for the treatment of patients with relapsed or refractory multiple myeloma. The designation is based on encouraging safety, efficacy, and durability signals

4 February 2026

Clinical Trials

Global AI in Medical Diagnostics Market Set for Exceptional Growth at a CAGR of ~22% by 2032 | DelveInsight

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Migraine Clinical Trial Analysis Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space

Myelodysplastic Syndrome Clinical Trial Pipeline Gains Momentum: 120+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

ALK Inhibitor Clinical Trial Pipeline Gains Momentum: 15+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

FDA Grants Orphan Drug Designation to CTD402, an Off‑the‑Shelf Anti‑CD7 CAR‑T Therapy, for Rare T‑Cell Leukemias and Lymphomas

Shilpa Medicare’s Biologicals Unit Secures FDA Orphan Drug Designation for Investigational Monoclonal Antibody Targeting Rare Blood Cancers

FDA Grants Breakthrough Therapy Designation to Bezuclastinib Plus Sutent for Advanced GIST After GLEEVEC Failure

Autism Spectrum Disorder Pipeline Insight 2025: Emerging Therapies, Clinical Trial Updates, and Regulatory Progress

The FDA Grants Fast Track Designation to Novel GPRC5D/CD3 Bispecific Antibody LBL‑034 for Relapsed/Refractory Multiple Myeloma

Recent Posts

Banner

Newsletter

Authors

pharmaglobenews

Michael Ashford

FDA Approves Otsuka’s VOYXACT (Sibeprenlimab-szsi): A Breakthrough in Primary Immunoglobulin A Nephropathy Treatment

Suggestions

Clinical Trials

Recent Posts

Banner

Newsletter

Authors